2023
CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediators
2022
Association of iron infusion reactions with ABO blood type
Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.Peer-Reviewed Original ResearchConceptsGreater oddsBlood typeYale Cancer CenterInfusion-related reactionsRetrospective chart reviewLarger patient numbersABO blood typeType AB bloodChart reviewInfusion reactionsMost patientsHematology clinicIron sucroseMultivariable analysisProspective studyCancer CenterPatient numbersIron dextranRisk factorsIron infusionIron repletionPatientsPossible associationAB bloodBlood
2021
Iron Infusion Reactions: Risk Factors and Real-World Experience
Butt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience. Blood 2021, 138: 4154. DOI: 10.1182/blood-2021-151048.Peer-Reviewed Original ResearchInfusion-related reactionsSeverity of IRRsHistory of CVDHistory of allergyCardiovascular diseaseBeta blockersOral ironPatient characteristicsRisk factorsLower oddsGreater oddsExact testAngiotensin-converting enzyme inhibitor useAssociation of CVDYale-New Haven HospitalEnzyme inhibitor useFirst-line therapyHeavy menstrual bleedingRetrospective chart reviewMajority of patientsAnti-inflammatory effectsMajor adverse effectsIron deficiency anemiaMultivariable regression analysisSeverity of reactions
2017
Anticoagulation for Proximal Deep Vein Thrombosis
Lee A, Lee E. Anticoagulation for Proximal Deep Vein Thrombosis. 2017, 299-313. DOI: 10.1007/978-3-319-65226-9_23.Peer-Reviewed Original ResearchDeep vein thrombosisVenous thromboembolismPulmonary emboliVein thrombosisProximal deep vein thrombosisMonths of anticoagulationProvoked venous thromboembolismUnprovoked venous thromboembolismEstimates of recurrenceLow recurrence riskRisk prediction modelExtended anticoagulationSurveillance ultrasonographyVTE eventsSuch patientsD-dimerSignificant morbidityThrombotic riskRisk factorsThrombophilia testingHigh riskAnticoagulationThrombosisRecurrenceRisk